Patents by Inventor Doris Meier

Doris Meier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240059758
    Abstract: The present invention is related to antibodies and antigen-binding fragments of antibodies that specifically bind the SARS-CoV-2 glycoprotein S (spike) as well as diagnostic and therapeutic methods of using those antibodies.
    Type: Application
    Filed: May 19, 2021
    Publication date: February 22, 2024
    Inventors: André Frenzel, Philipp Kuhn, Jonas Kügler, Michael Hust, Stefan Dübel, Doris Meier, Federico Bertoglio, Maren Schubert, Stephan Steinke, Marlies Becker, Viola Fühner, Maximilian Ruschig, Philip Alexander Heine, Kai-Thomas Schneider, Rico Ballmann, Susanne Zock-Emmenthal, Kristian Daniel Ralph Roth, Nora Langreder
  • Patent number: 11407819
    Abstract: The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (Efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, C3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: August 9, 2022
    Assignees: The Texas A&M University System, Technische Universität Braunschweig, Università Degli Studi Di Pavia
    Inventors: Ya-Ping Ko, Magnus Hook, Srishtee Arora, Livia Visai, Federico Bertoglio, Michael Hust, Doris Meier
  • Publication number: 20200283508
    Abstract: The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (Efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, C3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.
    Type: Application
    Filed: May 20, 2020
    Publication date: September 10, 2020
    Inventors: Ya-Ping Ko, Magnus Hook, Suzan HM Rooijakkers, Livia Visai, Federico Bertoglio, Michael Hust, Doris Meier
  • Publication number: 20070274985
    Abstract: The present invention refers to synthetic antibody molecules which comprise domains from naturally occuring antibodies, e.g. domains derivable from IgG, preferably of human origin, in a novel arrangement. Single chain molecules are provided which are suitable for expression in micro-organisms in their active conformation, which single chain molecules generally comprise a VL domain, a CL domain, and a VH domain, a CH1 domain, linked by a linker arranged between VUCL and VH/CH1. Accordingly, these antibody molecules can be termed single chain Fabs (scFabs). These antibody molecules are single chain proteins, which can also be associated to dimers, including heteromeric antibodies, wherein at least two single chain antibody molecules are associated.
    Type: Application
    Filed: May 26, 2006
    Publication date: November 29, 2007
    Inventors: Stefan Dubel, Martina Inga Kirsch, Michael Hust, Thomas Jostock, Doris Meier